DeCure's autonomous Nephrology AI scientist is researching a drug-repurposing hypothesis for renal osteodystrophy — screening already-approved drugs against its 35-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleRenal osteodystrophy maps to a 35-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for renal osteodystrophy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphodiesterase 4D (PDE4D) — PDE4D is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet difluoromethoxydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5WH6 · 1.6 Å · ligand 1-[4-(difluoromethoxy)-3-{[(3S)-oxolan-3-yl]oxy}phenyl]-3-methylbutan-1-one (AKJ). Experimental structure, not a prediction.
What the evidence adds up to
The 2014 review of renal osteodystrophy in children describes the fibroblast growth factor 23/Klotho system as central to pathogenesis, enhancing phosphate excretion and reducing calcitriol synthesis. Fibroblast growth factor 23 is independently associated with mortality and increases tissue calcinosis. The review states that new treatment options improved bone health and reduced mortality in adults with calcium-free phosphate binders, and that substitution of active and inactive vitamin D has a beneficial effect on proteinuria. No concrete survival or response rates are given for any intervention in children.
A separate 2014 literature review catalogues drug classes used for renal osteodystrophy: phosphate binders, vitamin D preparations, bisphosphonates, denosumab, and calcimimetics. It mentions a pilot study of teriparatide and denosumab on bone metabolism parameters in chronic kidney disease patients, but provides no numerical results, sample sizes, or efficacy conclusions from that study. A 1994 review states that the major unresolved issue in management is patient compliance, and lists three areas of controversy: calcitriol dosing, the use of bone biopsy, and the implications of aplastic bone disorder.
No randomised trial has yet demonstrated that any drug regimen reduces fractures or cardiovascular events specifically in children with renal osteodystrophy. The evidence base lacks prospective paediatric trials with hard endpoints, adequate funding for long-term studies, and validated stratification of patients by bone turnover type before treatment assignment.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Pediatrics · 2014 · 16 citations
Renal osteodystrophy in children
AbstractPURPOSE OF REVIEW: Disturbances in calcium-phosphate homeostasis play an important role in children with chronic kidney disease, and not only cause renal osteodystrophy but also result in increased cardiovascular morbidity and mortality. This review outlines the current aspects in the pathogenesis, diagnostic approach and treatment of renal osteodystrophy. RECENT FINDINGS: The pathogenesis of renal osteodystrophy is under strong influence of the fibroblast growth factor 23/Klotho system, which is able to enhance phosphate excretion and reduce calcitriol synthesis in the kidney. Fibroblast growth factor 23 increases tissue calcinosis and is cardiotoxic, and is independently associated with mortality. Despite improvement in diagnostic imaging (bone density measurements), determination of biomarkers, mainly parathyroid hormone, still plays a central role. New treatment options resulted in improved bone health and also a reduction in mortality was achieved in adults with calcium-free phosphate binders. Substitution of active and inactive vitamin D is important and also has a beneficial effect on proteinuria. SUMMARY: Knowledge about the biochemical and molecular mechanisms of renal osteodystrophy is increasing dramatically and has an impact not only to bone health but also overall morbidity and mortality. This will ultimately translate into further improved diagnostic approaches and novel treatment options.
Osteoporosis and Bone Diseases · 2014 · 2 citations · open access
MEDICAL METHODS OF CORRECTION OF RENAL OSTEODYSTROPHY
AbstractThe article presents a literature review summarizing the contemporary data on the effects of drug therapy on various parameters of renal osteodystrophy: phosphate binders, vitamin D preparations, bisphosphonates, denosumab, and calcimimetics. We discuss the results of pilot study of the efficacy of teriparatide and denosumab on parameters of bone metabolism in patients with chronic kidney disease.
AbstractSummary In this review I have briefly described the patho‐physiology of renal osteodystrophy, the kinds of bone lesions which occur, and the current thoughts about management, pointing out that the major issue we need to solve is patient compliance. I have also discussed three areas of controversy: calcitriol dosing, the use of the bone biopsy, and the implications of the recently noted aplastic bone disorder.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
